TNYA

Tenaya Therapeutics Inc

0.3610

Nov 02 • 3:59 PM ET -0.0064 (-1.74%)

0.3615

Aftermarket • 7:47 PM ET +0.0005 (0.14%)

Healthcare Biotechnology USA Micro NASD

Peers: LXEO RNA RCKT SLDB EWTX CYTK FDMT KARD RGNX QURE

| Held by: VTI VXF IBB PRFZ QQQS BTEC IBBQ BIB AVTM

Scroll to Statements

Index	-
Market Cap	82.28M
Enterprise Value	8.15M
Income	-103.11M
Sales	1.33M
Book/sh	0.31
Cash/sh	0.34
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	70
IPO	Jul 30, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	61.87
P/B	1.17
P/C	1.05
P/FCF	-
EV/EBITDA	-
EV/Sales	6.13
Quick Ratio	4.52
Current Ratio	4.52
Debt/Eq	0.06
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-0.53
EPS next Y	-0.37
EPS next Q	-0.10
EPS this Y	18.64%
EPS next Y	23.75%
EPS next 5Y	-
EPS past 3/5Y	40.12% 8.63%
Sales past 3/5Y	- -
EPS Y/Y TTM	45.08%
Sales Y/Y TTM	-
EPS Q/Q	-39.44%
Sales Q/Q	-
Earnings	Aug 05 AMC
EPS/Sales Surpr.	-192.83% -88.92%

Insider Own	1.34%
Insider Trans	-1.22%
Inst Own	25.25%
Inst Trans	-0.71%
ROA	-95.61%
ROE	-121.86%
ROIC	-146.31%
Gross Margin	-435.73%
Oper. Margin	-6192.88%
Profit Margin	-7723.97%
SMA20	-17.64%
SMA50	-36.42%
SMA200	-49.05%
Trades

Shs Outstand	227.93M
Shs Float	224.88M
Short Float	10.01%
Short Ratio	8.15
Short Interest	22.52M
52W High	1.56 -76.86%
52W Low	0.36 0.25%
Volatility	6.63% 8.95%
ATR (14)	0.03
RSI (14)	27.07
Beta	2.88
Rel Volume	0.83
Avg Volume	2.76M
Volume	2,291,896

Perf Week	-11.65%
Perf Month	-36.00%
Perf Quarter	-51.32%
Perf Half Y	-54.30%
Perf YTD	-49.26%
Perf Year	-74.93%
Perf 3Y	-83.36%
Perf 5Y	-98.59%
Perf 10Y	-
Recom	1.00
Target Price	9.33
Prev Close	0.37
Price	0.36
Change %	-1.74%

Consensus

Strong Buy

Avg. Price Target

$9.33

Implied Upside

+2,484.5%

Analysts3incl. previous ratings

Rating Distribution3 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jun 10, 2024	Initiated	WWilliam Blair	Outperform
Nov 30, 2023	Initiated	LLeerink Partners	Outperform	$7	+1,839.1%
Jun 15, 2022	Initiated	HH.C. Wainwright	Buy	$25	+6,825.2%

Sep-14-26 08:30AM	Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (GlobeNewswire) +8.27%
Sep-10-26 09:56AM	Treasury yields rise as investors raise bets on Fed rate hike: AlphaCheck (Yahoo Finance)
Sep-03-26 04:30PM	Tenaya Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-05-26 04:05PM	Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +5.81% -7.51%
Aug-04-26 04:05PM	Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference (GlobeNewswire)
09:00PM	Loading…
Jul-14-26 09:00PM	Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-29-26 08:30AM	Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer (GlobeNewswire)
Jun-03-26 07:00AM	Tenaya Therapeutics Announces Interim Data from MyPEAK-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms (GlobeNewswire)
Jun-02-26 04:30PM	Tenaya Therapeutics to Announce New Interim Data from MyPEAK-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 (GlobeNewswire) -9.20%
May-29-26 08:00AM	Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026 (GlobeNewswire) +8.77%
May-15-26 06:01AM	Positive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC (GlobeNewswire) -8.31%
May-06-26 04:05PM	Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +7.37%
Apr-27-26 08:30AM	Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026 (GlobeNewswire)
Mar-11-26 04:05PM	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-09-26 08:30AM	Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy (GlobeNewswire) +7.84%
07:19AM	Loading…
Mar-06-26 07:19AM	Alnylam and Tenaya sign $1.23bn cardiovascular target discovery deal (Pharmaceutical Technology) +8.39%
Mar-05-26 01:35PM	Tenaya Therapeutics Stock Jumps After New Alnylam Deal (Benzinga) +40.92%
08:30AM	Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics (GlobeNewswire)
Mar-02-26 04:05PM	Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026 (GlobeNewswire)
Jan-19-26 08:01AM	Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026 (Insider Monkey)
Jan-12-26 04:23AM	Morgan Stanley Reduces PT on Tenaya Therapeutics (TNYA), Keeps Constructive Stance on U.S. Small- to Mid-Cap Biotech (Insider Monkey)
Jan-09-26 08:30AM	Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Dec-12-25 12:16AM	Tenaya Therapeutics Announces Pricing of Public Offering (GlobeNewswire) -37.50%
Dec-11-25 04:02PM	Tenaya Therapeutics Announces Proposed Public Offering (GlobeNewswire)
04:01PM	Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC (GlobeNewswire)
04:01PM	Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy (GlobeNewswire)
Nov-10-25 07:00AM	Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +11.72%
Nov-08-25 11:25AM	Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy (GlobeNewswire)
Nov-04-25 05:30PM	Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025 (GlobeNewswire)
Oct-09-25 04:05PM	Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference (GlobeNewswire) +10.38%
04:05PM	Loading…
Oct-02-25 04:05PM	Tenaya Therapeutics to Participate in Upcoming October Investor Conferences (GlobeNewswire)
Sep-18-25 04:05PM	Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +8.20% +6.82%
Sep-02-25 04:05PM	Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire) +9.26%
Aug-31-25 10:15AM	Tenaya Therapeutics Presents Interim Data from MyClimb Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025 (GlobeNewswire)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +8.62%
Aug-08-25 08:00AM	Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Aug-07-25 05:15AM	Clinical trial supply chains in the US navigate pharma tariffs (Clinical Trials Arena)
Aug-06-25 04:30PM	Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-30-25 08:30AM	Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed (GlobeNewswire)
May-15-25 09:00PM	Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +12.74%
May-13-25 08:30AM	Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting (GlobeNewswire)
May-07-25 04:05PM	Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-24-25 02:07PM	Tenaya Therapeutics Presents Interim Data from RIDGE Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025 (GlobeNewswire)
Apr-01-25 12:26PM	Tenaya highlights HCM gene therapy interim data at ACC 2025 (Clinical Trials Arena)
Mar-31-25 10:00AM	Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK -1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting (GlobeNewswire) -11.25%
Mar-28-25 10:43AM	Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March? (Insider Monkey) -7.14%
Mar-25-25 11:27AM	Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey) -6.61%
09:18AM	Top 3 Insider Stock Buys in March-Are They Still Good in April? (MarketBeat)
08:45AM	Tenaya Therapeutics publishes preclinical data on TN-201 in cardiac function (TipRanks)
Mar-24-25 08:30AM	Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models (GlobeNewswire) +9.96%
Mar-19-25 08:30AM	Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session (GlobeNewswire)
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-10-25 04:05PM	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) +11.14% +6.78%
Mar-03-25 11:19PM	Tenaya Therapeutics Announces Pricing of Public Offering (GlobeNewswire) -6.25% -53.53%
04:10PM	Tenaya Therapeutics Announces Proposed Public Offering (GlobeNewswire)
08:00AM	Tenaya Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-03-25 08:30AM	Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine (GlobeNewswire)
Jan-13-25 09:16AM	Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Dec-17-24 07:00AM	Tenaya Therapeutics Reports Promising Early Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy (GlobeNewswire) -51.04%
Dec-16-24 04:30PM	Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 (GlobeNewswire)
Nov-25-24 08:30AM	Tenaya Therapeutics Doses First Patient in RIDGE-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (GlobeNewswire) +24.37%
Nov-19-24 08:00AM	Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +10.19%
Nov-06-24 04:05PM	Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +12.11%
Nov-03-24 06:11AM	Morgan Stanley Predicts Up to 670% Jump for These 2 Strong Buy Stocks (TipRanks)
Oct-17-24 04:30PM	Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM (GlobeNewswire) +22.86% -5.12%
Sep-03-24 08:30AM	Tenaya Therapeutics to Participate in Upcoming Investment Conferences (GlobeNewswire) -5.60%
Aug-08-24 04:05PM	Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.10%
Jun-27-24 05:00PM	Tenaya Therapeutics Announces Research Leadership Updates (GlobeNewswire) +8.09% +5.44%
Jun-18-24 04:30PM	Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit (GlobeNewswire)
May-16-24 12:21PM	Canaccord Genuity Adjusts Tenaya Therapeutics Price Target to $16 From $18, Maintains Buy Rating (MT Newswires)
May-15-24 07:00AM	Novo Holdings buys stake in life sciences tools company; BioMarin lays off 170 (BioPharma Dive)
May-14-24 10:54PM	TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-12-24 03:26PM	13 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-02-24 05:00PM	Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting (GlobeNewswire)
Mar-26-24 07:19AM	20 Countries with the Highest Heart Disease Deaths Per Capita (Insider Monkey)
Mar-20-24 05:32AM	Tenaya Therapeutics Inc Reports Full Year and Q4 2023 Financial Results (GuruFocus.com) +8.17%
Mar-18-24 10:53PM	TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -6.02%
04:05PM	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
08:30AM	Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
Feb-27-24 04:30PM	Tenaya Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-26-24 09:55AM	Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross? (Zacks) +9.00%
08:30AM	Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications (GlobeNewswire)
Feb-09-24 09:55AM	Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet (Zacks) +10.72%
Feb-08-24 08:00AM	Tenaya Therapeutics Announces Pricing of Underwritten Offering (GlobeNewswire) +16.06%
Jan-26-24 12:00PM	Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why (Zacks)
Jan-03-24 08:30AM	Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.28%
Nov-21-23 04:30PM	Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-08-23 04:05PM	Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-26-23 08:30AM	Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (GlobeNewswire) -5.67%
Oct-09-23 08:30AM	Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting (GlobeNewswire)
Oct-05-23 08:30AM	Tenaya Therapeutics Doses First Patient in the MyPeak-1 Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy (GlobeNewswire)
Oct-02-23 05:30PM	Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration (GlobeNewswire) -5.24%
Sep-21-23 04:05PM	Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences (GlobeNewswire) +6.06%
Aug-31-23 04:05PM	Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference (GlobeNewswire) -5.38%
Aug-09-23 04:05PM	Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +5.50%
Aug-02-23 04:05PM	Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference (GlobeNewswire)
May-30-23 09:06AM	With 35% stake, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) seems to have captured institutional investors' interest (Simply Wall St.)
May-15-23 09:55AM	Wall Street Analysts Believe Tenaya Therapeutics, Inc. (TNYA) Could Rally 217.58%: Here's is How to Trade (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ali Faraz	Chief Executive Officer	Aug 17 '26	Sale	0.71	22,232	15,778	417,782	Aug 17 08:50 PM
Tingley Whittemore	Chief Medical Officer	Aug 17 '26	Sale	0.71	7,424	5,270	214,073	Aug 17 08:49 PM
Faraz Ali	Officer	Aug 17 '26	Proposed Sale	0.71	22,232	15,778		Aug 17 08:46 PM
Whittemore Tingley	Officer	Aug 17 '26	Proposed Sale	0.71	7,424	5,270		Aug 17 08:45 PM
Ali Faraz	Chief Executive Officer	May 18 '26	Sale	0.79	3,390	2,690	440,014	May 19 07:09 PM
Tingley Whittemore	Chief Medical Officer	May 18 '26	Sale	0.79	3,121	2,477	215,497	May 19 07:09 PM
Higa Tomohiro	SVP, Finance	May 18 '26	Sale	0.79	1,485	1,178	118,267	May 19 07:06 PM
COLUMN GROUP III GP, LP	10% Owner	Feb 25 '26	Sale	0.56	3,511,826	1,975,051	0	Feb 26 04:23 PM
COLUMN GROUP III GP, LP	10% Owner	Feb 24 '26	Sale	0.62	658,440	405,138	1,649,281	Feb 26 04:23 PM
COLUMN GROUP III, LP	10% Owner	Feb 25 '26	Proposed Sale	0.60	939,273	565,442		Feb 25 05:05 PM
COLUMN GROUP III-A, LP	10% Owner	Feb 25 '26	Proposed Sale	0.56	1,060,727	596,553		Feb 25 05:04 PM
COLUMN GROUP III GP, LP	10% Owner	Feb 20 '26	Sale	0.61	523,734	322,044	2,102,218	Feb 24 04:13 PM
COLUMN GROUP III GP, LP	10% Owner	Feb 23 '26	Sale	0.60	306,000	182,743	1,958,509	Feb 24 04:13 PM
COLUMN GROUP III, LP	10% Owner	Feb 20 '26	Proposed Sale	0.62	1,408,910	872,538		Feb 20 05:37 PM
COLUMN GROUP III-A, LP	10% Owner	Feb 20 '26	Proposed Sale	0.62	1,591,090	985,362		Feb 20 05:35 PM
Higa Tomohiro	SVP, Finance	Feb 17 '26	Sale	0.64	3,469	2,231	119,752	Feb 17 07:15 PM
Ali Faraz	Chief Executive Officer	Feb 17 '26	Sale	0.64	14,862	9,557	443,404	Feb 17 07:14 PM
Tingley Whittemore	Chief Medical Officer	Feb 17 '26	Sale	0.64	5,160	3,319	218,618	Feb 17 07:13 PM
Faraz Ali	Officer	Feb 17 '26	Proposed Sale	0.64	14,862	9,557		Feb 17 07:12 PM
Whittemore Tingley	Officer	Feb 17 '26	Proposed Sale	0.64	5,160	3,319		Feb 17 07:09 PM
COLUMN GROUP III GP, LP	10% Owner	Feb 11 '26	Sale	0.68	4,056,573	2,761,715	2,348,183	Feb 12 05:19 PM
COLUMN GROUP III GP, LP	10% Owner	Feb 10 '26	Sale	0.82	343,717	280,507	4,253,298	Feb 12 05:19 PM
COLUMN GROUP III-A, LP	10% Owner	Feb 11 '26	Proposed Sale	0.68	742,663	504,788		Feb 11 05:57 PM
COLUMN GROUP III, LP	10% Owner	Feb 11 '26	Proposed Sale	0.68	657,627	446,989		Feb 11 05:52 PM
COLUMN GROUP III-A, LP	10% Owner	Feb 10 '26	Proposed Sale	0.79	1,591,090	1,256,961		Feb 10 05:25 PM
COLUMN GROUP III, LP	10% Owner	Feb 10 '26	Proposed Sale	0.79	1,408,910	1,113,038		Feb 10 05:06 PM
Higa Tomohiro	SVP, Finance	Nov 17 '25	Sale	1.33	1,367	1,818	93,971	Nov 17 08:34 PM
Tingley Whittemore	Chief Medical Officer	Nov 17 '25	Sale	1.33	2,877	3,826	169,926	Nov 17 08:34 PM
Ali Faraz	Chief Executive Officer	Nov 17 '25	Sale	1.33	3,126	4,158	299,666	Nov 17 08:33 PM

Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. Its programs include TN-201, TN-401, and TN-301. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Newell Olson in 2016 and is headquartered in South San Francisco, CA.

PresidentMr. Faraz Ali M.B.A.

Scientific FounderDr. Deepak Srivastava M.D.

PH.D.Dr. Whittemore G. Tingley M.D.

Scientific Founder & Member of Scientific Advisory BoardDr. Eric N. Olson Ph.D.

Scientific FounderDr. Bruce R. Conklin M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TNYA

Tenaya Therapeutics Inc

Upgrade your Finviz experience